Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Prevalence of Human T-Lymphotropic Virus Type 1 (Htlv-1) Infection in Patients With Hematologic Disorders and Non-Hematologic Malignancies in a Tertiary Referral Hospital Pubmed



Jalaeikhoo H1 ; Soleymani M2 ; Rajaeinejad M1 ; Keyhani M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. AJA Cancer Research Center (ACRC), AJA University of Medical Sciences, Tehran, Iran
  2. 2. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Hematology and Oncology Research Center, Vali-Asr Hospital Tehran University of Medical Sciences, Tehran, Iran

Source: Archives of Iranian Medicine Published:2017


Abstract

Background: Human T-lymphotropic virus type 1 (HTLV-1) was the first retrovirus identified in human. The current evidence is quite scarce regarding the potential role of HTLV-1 in pathogenesis of hematologic disorders and non-hematologic malignancies. Objectives: The aim of this study is to evaluate the prevalence of HTLV-1 infection in patients with hematologic disorders and non- hematologic malignancies. Methods: This cross-sectional study was conducted on 505 cases of definite diagnosis of hematologic disorders including malignancies as well as non-malignant disorders such as polycythemia and myelofibrosis and non-hematologic malignancies referred to the hematology and medical oncology ward at Army Hospital 501 from January 2015 to January 2016. A 3-mL blood specimen was collected from each patient and tested for the presence of anti-HTLV-1 antibodies using enzyme-linked immunosorbent assay (ELISA). Data were analyzed using SPSS software package version 19 (IBM, NewYork, USA). Data are presented as mean ± SD if normally distributed and otherwise as median (range). Results: Totally, 242 (48%) males and 263 (52%) females with a mean ± SDage of 52.09 ± 16.24 were enrolled in this study. In total, there were 9 (1.78%) cases positive for HTLV-1 infection including 4 males and 5 females. Seven out of 287 (2.4%) patients with hematologic disorders were infected by HTLV-1. In non-hematologic malignancies, 2 out of 211 cases were positive (0.9%). There was no HTLV-1 positive case in 7 patients with both hematologic and non-hematologic disorders. The difference in HTLV-1 infection prevalence between patients with hematologic disorders and non-hematologic malignancies was not statistically significant different (P = 0.31). There was no association between sex and transfusion history with HTLV-1 infection in this population (P = 0.9 and 0.7, respectively). Conclusions: Our study revealed that the prevalence of HTLV-1 in hematologic disorders is higher than the general population. Further larger prospective studies are recommended to corroborate the current evidence. © 2017, Academy of Medical Sciences of I.R. Iran. All rights reserved.
Other Related Docs